抗喘药物基因组学的研究进展.pdfVIP

抗喘药物基因组学研究进展 1，2 1，2 1∗ 朱琳 ，邓婕 ，宋洪涛 1 （南京军区福州总医院药学科，福州350025，福建； 2 沈阳药科大学药学院，沈阳110016，辽宁） 摘要：β2 受体激动剂，白三烯调节剂和糖皮质激素三类常用抗哮喘药物的疗效非常显著，但 是仍有高达50%的哮喘患者对这些药物中的一种或多种没有反应。大量的证据表明哮喘的治 疗效果和不良反应在个体间存在很大的差异。哮喘药物基因组学的文献显示遗传变异能够影 响哮喘的治疗效果，这一结论可以用于指导用药前的预测试验，以减少不良反应的发生，增 强疗效。这篇综述概括性论述了哮喘相关基因组学的研究结果以及三类常用抗哮喘药物的基 因组学研究进展。 关键词：哮喘；药物基因组学；β 受体激动剂；白三烯；糖皮质激素 2 Advances in research on pharmacogenomics of asthma ZHU Lin1, 2, DENG Jie1, 2, SONG Hong-tao1* 1 ( Department of pharmacy, Fuzhou General Hospital of Nanjing Military Region, Fuzhou 350025; 2Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China) Abstract: Despite the availability of several classes of asthma medications such as β-agonists, 2 leukotriene modifiers and corticosteroids, up to 50% of asthmatics do not benefit from one or more of these drugs. Evidence indicates that there is a large amount of inter-individual variability in both therapeutic and adverse responses to asthma therapies. literature in asthma pharmacogenomics demonstrates that genetic variants influence response to asthma treatments and may be used for predictive testing prior to drug administration to avoid adverse reactions and increase drug efficacy. In this article we describe the most important and recent results of studies on asthma genomes. Next, we explore the findings of pharmacogenomic investigations on the three main classes of asthma medications. Key words: asthma; pharmacogenomics; β2-agonists; leukotrienes; co